RECKITT BENCKIS/S (RBGLY) Given Average Recommendation of “Buy” by Analysts
RECKITT BENCKIS/S (OTCMKTS:RBGLY) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company.
Several equities analysts have weighed in on RBGLY shares. Zacks Investment Research lowered RECKITT BENCKIS/S from a “hold” rating to a “sell” rating in a research note on Saturday, October 6th. BNP Paribas raised RECKITT BENCKIS/S from a “neutral” rating to an “outperform” rating in a research note on Tuesday.
Shares of RBGLY traded up $0.33 during trading hours on Tuesday, hitting $16.91. 646,731 shares of the stock traded hands, compared to its average volume of 184,107. RECKITT BENCKIS/S has a 1-year low of $15.14 and a 1-year high of $21.79. The company has a quick ratio of 0.50, a current ratio of 0.68 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $59.31 billion, a PE ratio of 24.16, a price-to-earnings-growth ratio of 4.36 and a beta of 1.03.
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Recommended Story: What is a bull market?
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.